Why did reported revenue decline if the business grew?

Reported revenue fell 4% to $52.3 billion because of the expiration of a large customer contract, which was tied to OptumRx revenue of $9.3 billion in the prior-year quarter. Excluding that revenue, first-quarter revenue grew 15%, mainly from brand and specialty pharmaceutical sales to existing customers.

Why did GAAP results swing so much from the prior year?

The prior-year first quarter included a $585 million pre-tax goodwill impairment in the GMPD segment, which produced a GAAP operating loss of $32 million. This year's GAAP operating earnings of $568 million therefore compare against a depressed base and are not a like-for-like improvement in underlying performance. Non-GAAP operating earnings, which exclude such items, grew 12%.

Why was guidance raised even though GMPD's outlook was cut?

The raise was driven by stronger expected performance in the Pharmaceutical and Specialty Solutions segment, where profit growth guidance moved up to 4%–6% from 1%–3%. The GMPD profit cut, to $140–$175 million from about $175 million, was primarily due to higher health and welfare costs and was more than offset at the enterprise level.

Why is adjusted free cash flow negative this quarter, and should investors be concerned?

Operating cash flow was negative $1.65 billion, largely from a $1.39 billion decline in accounts payable and higher inventory build, as well as other working capital changes. Adjusted free cash flow was negative $1.36 billion versus positive $978 million a year earlier. Quarterly swings in working capital are common for this distributor, and management nonetheless raised its full-year adjusted free cash flow outlook to $1.0–$1.5 billion.

What are the key risks highlighted in the filing?

The filing cites risks including customer contract losses or non-renewals, uncertainty over branded drug pricing and possible legislation, ongoing IRS audits that could raise the effective tax rate, a Department of Justice investigation into potential Anti-Kickback Statute and False Claims Act violations, generic drug deflation, supply disruptions, and potential impairment of the At-Home unit's goodwill.

CAH 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed November 1, 2024. Cited figures are marked; the original filing is the authoritative source.

Cardinal Health (CAH) reported first-quarter fiscal 2025 results (quarter ended September 30, 2024) that beat on profitability and led management to raise its full-year non-GAAP EPS guidance.

Reported revenue fell 4% to $52.3 billion^a, but revenue rose 15% excluding the previously announced expiration of a large customer contract (OptumRx). GAAP operating earnings were $568 million and GAAP diluted EPS was $1.70, compared with a GAAP operating loss in the prior year that included a $585 million goodwill impairment in the Global Medical Products and Distribution (GMPD) segment. Non-GAAP operating earnings rose 12% to $625 million, and non-GAAP diluted EPS rose 9% to $1.88, helped by a lower share count from buybacks.

The quarter's strength came mainly from the Pharmaceutical and Specialty Solutions (PSS) segment, where profit grew 16% to $530 million^b on brand and specialty product growth, an early start to COVID-19 vaccine distribution, and generics performance. Management raised fiscal 2025 non-GAAP EPS guidance to $7.75–$7.90 from $7.55–$7.70 and lifted PSS segment profit growth to 4%–6% from 1%–3%. Offsetting this, GMPD segment profit fell to $8 million and its full-year outlook was cut to $140–$175 million from about $175 million, mainly due to higher health and welfare costs.

Adjusted free cash flow was negative $1.36 billion^c in the quarter, but full-year guidance was raised to $1.0–$1.5 billion. Investors should also note the balance sheet and capital allocation moves. Cash fell to $2.87 billion from $5.13 billion at June 30, 2024, reflecting a $1.65 billion operating cash outflow driven by working capital, including a $1.39 billion decline in accounts payable.

The company completed a $375 million^d accelerated share repurchase in October and has a pending $1.1 billion cash acquisition of Integrated Oncology Network (ION). The filing also notes continuing risks, including a Department of Justice investigation into potential Anti-Kickback Statute and False Claims Act violations, IRS audits, and drug pricing uncertainty.

02—Key points

Key Highlights

Reported revenue declined 4% to $52.3 billion, but grew 15% excluding the expired large customer contract, driven by brand and specialty pharmaceutical growth.
GAAP diluted EPS of $1.70 and GAAP operating earnings of $568 million, versus a prior-year GAAP loss that included a $585 million GMPD goodwill impairment.
Non-GAAP operating earnings rose 12% to $625 million and non-GAAP diluted EPS rose 9% to $1.88.
PSS segment profit grew 16% to $530 million, while GMPD segment profit fell to $8 million from $12 million.
Fiscal 2025 non-GAAP EPS guidance raised to $7.75–$7.90 from $7.55–$7.70; PSS profit growth outlook raised to 4%–6%; GMPD profit outlook lowered to $140–$175 million.
Adjusted free cash flow was negative $1.36 billion in the quarter, but full-year guidance was raised to $1.0–$1.5 billion from about $1.0 billion.
Pending $1.1 billion cash acquisition of Integrated Oncology Network, and a $375 million accelerated share repurchase completed in October.

03—Questions

Frequently Asked Questions

Why did reported revenue decline if the business grew?
Reported revenue fell 4% to $52.3 billion because of the expiration of a large customer contract, which was tied to OptumRx revenue of $9.3 billion in the prior-year quarter. Excluding that revenue, first-quarter revenue grew 15%, mainly from brand and specialty pharmaceutical sales to existing customers.
Why did GAAP results swing so much from the prior year?
The prior-year first quarter included a $585 million pre-tax goodwill impairment in the GMPD segment, which produced a GAAP operating loss of $32 million. This year's GAAP operating earnings of $568 million therefore compare against a depressed base and are not a like-for-like improvement in underlying performance. Non-GAAP operating earnings, which exclude such items, grew 12%.
Why was guidance raised even though GMPD's outlook was cut?
The raise was driven by stronger expected performance in the Pharmaceutical and Specialty Solutions segment, where profit growth guidance moved up to 4%–6% from 1%–3%. The GMPD profit cut, to $140–$175 million from about $175 million, was primarily due to higher health and welfare costs and was more than offset at the enterprise level.
Why is adjusted free cash flow negative this quarter, and should investors be concerned?
Operating cash flow was negative $1.65 billion, largely from a $1.39 billion decline in accounts payable and higher inventory build, as well as other working capital changes. Adjusted free cash flow was negative $1.36 billion versus positive $978 million a year earlier. Quarterly swings in working capital are common for this distributor, and management nonetheless raised its full-year adjusted free cash flow outlook to $1.0–$1.5 billion.
What are the key risks highlighted in the filing?
The filing cites risks including customer contract losses or non-renewals, uncertainty over branded drug pricing and possible legislation, ongoing IRS audits that could raise the effective tax rate, a Department of Justice investigation into potential Anti-Kickback Statute and False Claims Act violations, generic drug deflation, supply disruptions, and potential impairment of the At-Home unit's goodwill.

04—Continue

← View all 8-K filings